The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group,
placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of
TLL018 as therapy in 120 participants with moderate-to-severe PP.